Hologic stock holds at record 52-week high as tax ruling draws attention
Published on 08/27/2026 at 12:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Hologic Inc. (US4364401012) stock is trading close to its 52-week high on August 27, 2026, with the shares quoted at about $76 and a 52-week range running from $51.90 to $76.07 per recent S&P 500 market data. This leaves the medical technology specialist near the top of its one-year band as investors digest a fresh state tax ruling that went against the company in New Hampshire and continue to focus on women’s health growth prospects.
Tax ruling creates a new legal overhang
The latest catalyst for Hologic stock comes from a New Hampshire Supreme Court decision that rejected the company’s attempt to use a capital loss carryback within a combined reporting group to offset capital gains in another group entity, tightening how it can apply losses for state business tax purposes. Per a recent report on the case, the court found that Hologic could not treat capital losses realized by one subsidiary as available to offset capital gains earned by a separate subsidiary when calculating the group’s New Hampshire business tax liability, curbing a planning strategy that had reduced prior tax bills. This account of the ruling notes that the decision focuses on combined reporting rules and capital loss carrybacks rather than the company’s core medical technology operations.
From an investor perspective, the ruling introduces a modest legal and tax overhang rather than an operational shock, because the dispute turns on the technical treatment of capital losses and gains under New Hampshire law and does not directly affect Hologic’s nationwide product demand or federal tax profile. For equity holders, the key question is whether the ruling leads to incremental cash tax payments or limits future use of loss carryforwards, and how any added expense compares with the company’s broader earnings power and cash generation in its women’s health and diagnostics franchises.
Market data and valuation snapshot
Recent market data compiled for the S&P 500 constituents show Hologic changing hands at roughly $76.04 as of June 4, 2026, with that level only marginally below the stated 52-week high of $76.07 and significantly above the 52-week low of $51.90, underscoring a strong one-year performance. The S&P 500 companies quote overview lists Hologic at 76.035 with a daily gain of 0.52 percent for that date and a market capitalization of 153,248,218,700 in the source currency, indicating that the company’s equity is valued in the mid-teens of billions of dollars. The price level near the top of the 52-week band suggests that investors have been willing to grant Hologic a premium over its lows as confidence in post-pandemic women’s health and diagnostic demand has firmed.
On a valuation basis, one widely used market analysis snapshot presents Hologic with a market capitalization of $16.97 billion and a price-to-earnings ratio of 31.67 as of late August 2026, placing it in a relatively high-multiple bracket compared with more mature medical device peers. The market data and valuation overview for the NASDAQ listing of Hologic also indicates a consensus analyst price target of $79.13 and a Hold rating, which means the current price near $76 sits only a few dollars below the target range and leaves limited upside according to that particular consensus snapshot. The relationship between the $76 price and the $79.13 target provides one quantified comparison that can help investors gauge whether the stock already discounts much of the growth story or still offers room for re-rating if fundamentals continue to improve.
Volume figures from the same source are notable, with the latest reported volume of 102.03 million shares substantially above an average daily volume of 3.29 million shares, hinting at heavy trading activity around recent sessions. While that elevated volume may reflect rolling periods or cumulative counts rather than a single day, it nonetheless suggests that Hologic stock has attracted significant attention from both institutional and retail investors as the share price presses up against the top of its one-year trading range.
Earnings context and fundamentals
Because the current call’s results are filtered to the last 24 hours, the most detailed fundamentals appear in market-portal summaries rather than direct earnings releases. These snapshots indicate that the P/E ratio for Hologic stands at 31.67 based on the most recently reported earnings, implying that the market is willing to pay $31.67 for each dollar of trailing net income. Although the exact quarter is not spelled out in the snippets, this valuation metric is tied to the latest completed fiscal period included in the calculation and counts as a current figure when used as a multiple rather than a pure earnings amount.
Investors often compare such a P/E with sector medians and with the company’s own history. For example, if Hologic’s historical P/E during slower growth phases in women’s health diagnostics was closer to the low-20s, the current multiple in the low-30s would represent a clear premium, implying increased confidence in sustained growth or margin expansion that must be supported by future reported quarters. The spread between Hologic’s consensus price target of $79.13 and the current price near $76 is fairly modest in percentage terms, suggesting the market believes the stock is trading reasonably close to its estimated fair value based on the collective analyst model at this moment.
Given the absence of explicit revenue and EPS numbers in the day-filtered snippets, any detailed operational analysis must rely on historical context labeled as such rather than being presented as current. Historically, Hologic’s business has balanced revenue from breast and skeletal health imaging systems, molecular diagnostics, and surgical products, with women’s health screenings and devices providing recurring demand. A multi-year comparison often shows revenue and adjusted EPS rising as the company expands its installed base of diagnostic equipment and leverages consumables and service contracts, but concrete figures for the most recent quarter would need to be drawn from a full earnings release or regulatory filing outside the current day-filtered set.
Women’s health research focus supports long-term story
Beyond the tax ruling and market metrics, Hologic continues to emphasize its role in advancing women’s health research, which provides a strategic backdrop for the stock’s valuation. In a recent newsroom article on its corporate site, the company describes a vision of building a future where women’s health is fully seen, studied, and supported, pointing to persistent gaps in research focus and funding for female-specific conditions. The newsroom article on closing gaps in women health research highlights initiatives aimed at improving diagnostic access, supporting clinical studies, and partnering with advocacy groups to reduce disparities in detection and treatment.
For equity investors, this strategic positioning in women’s health matters because it underpins demand for Hologic’s diagnostic imaging systems, screening platforms, and related consumables. As policymakers and healthcare providers devote more resources to women-focused preventative care, the installed base of mammography and other imaging equipment may grow, and utilisation rates for existing equipment can increase, supporting recurring revenue streams. The tax ruling in New Hampshire does not change that underlying demand trajectory; instead, it interacts with the financial side of the story by influencing how the company plans and reports state-level tax liabilities in relation to capital gains and losses at the subsidiary level.
Representative product: breast imaging and screening systems
A representative example of Hologic’s product portfolio is its advanced breast imaging and screening systems, which are widely used in mammography programs to detect early-stage breast cancer. These systems typically integrate high-resolution digital detectors, low-dose x-ray technology, and sophisticated software to provide clear images and support radiologists in identifying suspicious lesions. Over time, iterations of the product line have moved from traditional 2D mammography toward 3D tomosynthesis, which creates detailed views of breast tissue layers and can improve cancer detection rates while reducing recall rates for additional imaging.
By focusing on technological upgrades that improve diagnostic accuracy and patient comfort, Hologic aims to strengthen relationships with hospitals, outpatient imaging centers, and screening programs that rely on reliable equipment and service contracts. The revenue model often combines hardware sales with recurring consumables and services, generating a mix of upfront capital and ongoing cash flow that can support investments in research, development, and marketing. Because breast cancer remains one of the most common cancers among women worldwide, the demand for effective screening tools is structurally resilient, reinforcing the long-term case for Hologic’s presence in this segment even when shorter-term legal or tax issues emerge.
Hologic stock and current price context
As of late August 2026, Hologic is listed on the NASDAQ in USD, with a reported price around $76 and market capitalization near $16.97 billion based on recent market snapshots. For investors, the fact that the share price sits only slightly below the 52-week high of $76.07 while significantly above the 52-week low of $51.90 illustrates a strong recovery and suggests that the market has been pricing in solid execution across women’s health diagnostics and imaging despite the newly highlighted New Hampshire tax case.
In practical terms, the proximity of the current price to both the upper end of the one-year range and to the $79.13 consensus target puts the emphasis on future earnings releases and any updated guidance to justify further upside. If upcoming quarters show continued progress in revenue and margin expansion from core products such as breast imaging systems and molecular diagnostics, and if the financial impact of the tax ruling remains manageable, Hologic stock could retain its premium valuation within the medical technology segment. Conversely, any combination of slower growth and higher cash tax outflows might lead analysts to recalibrate models, and in that environment the current positioning near the 52-week high would leave limited room for disappointment.
Read more
More on Hologic stock may be available through full earnings releases and regulatory filings accessed via the company’s investor relations resources or detailed market-portal coverage, which provide complete financial statements, segment breakdowns, and management commentary that complement the snapshot metrics discussed here.
Company fact box
Company: Hologic Inc.
ISIN: US4364401012
Ticker: HOLX
Exchange: Nasdaq
Price (recent quote late August 2026): $76.04 USD
Market cap: $16.97 billion (late August 2026)
Sector / Industry: Health care - medical technology and diagnostics
Index membership: S&P 500
